Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early identification of patients who benefit from palbociclib in addition to letrozole
2015-004231-12Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib and letrozole in breast cancer, sponsored by University Medical Center Groningen. Primary endpoint: Primary: Relation between low uptake on 18F-FES PET and lesion-level response. Started Mar 2016; status: completed.
02
Drugs
palbociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-004231-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004231-12.